 Innate Pharma SA NASDAQ: IPHA has announced its Phase 2 FORCE trial evaluating avdoralimab in COVID-19 patients with severe pneumonia did not meet its primary endpoints in all three cohorts trial. Based on these results, the Company will stop exploring avdoralimab in COVID-19. 